Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.54 |
| ▸ | TP53 | P04637 | 3/20 | 0.54 |
| ▸ | CASP3 | P42574 | 2/20 | 0.49 |
| ▸ | TLR2 | O60603 | 4/20 | 0.49 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178739 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119686 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29398457 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29400667 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL118173 | 1.00 | MDM4 (0.54) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL23722984 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119456 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL119459 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL29709621 | 0.99 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 | |
| SCHEMBL22581595 | 0.97 | MDM4 (0.55) | MDM4TP53CASP3TLR2MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | BACOBA AG (CH) | 2024-05-30 | — | — | US | disclosed |
| WO-2022234853-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | 中外製薬株式会社 | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | MDM4 455/4885TP53 8/4885CASP3 2833/4885 |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | HRH4, NR1H4, NR1H3 | MDM4 3823/4885TP53 4245/4885CASP3 2686/4885 |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | MDM4 2280/4885TP53 190/4885CASP3 1188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.